Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1726-1735

  Paré, Pierre ^a   Gray, James ^b   Lam, Sy ^c   Balshaw, Robert ^d   Khorasheh, Shideh ^d   Barbeau, Martin ^e   Kelly, Suzanne ^e   McBurney, Christopher R ^f  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CALGARY HEALTH REGION   (Canada)

^d Syreon Corporation   (Canada)

^e Novartis   (Canada)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

EQ 5D; IBS; IBS QOL; quality of life; resource utilization; work productivity; WPAI

Indexed keywords

BULKING AGENT; DOMPERIDONE; HERBACEOUS AGENT; LAXATIVE; LOPERAMIDE; PINAVERIUM; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; SPASMOLYTIC AGENT; TEGASEROD;

ABDOMINAL PAIN; ABSENTEEISM; ADULT; AGE DISTRIBUTION; ARTICLE; ATTITUDE TO HEALTH; BLOATING; CANADA; CONSTIPATION; CONTROLLED STUDY; DATA COLLECTION METHOD; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISTRESS SYNDROME; FEMALE; FOLLOW UP; FOOD AVERSION; GASTROINTESTINAL SYMPTOM; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; IRRITABLE COLON; JOB PERFORMANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PHYSICIAN ATTITUDE; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SELF REPORT; TREATMENT OUTCOME; WORK CAPACITY; WORK DISABILITY;

ADULT; EFFICIENCY; FEMALE; HEALTH SERVICES; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 33751574668     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.010     Document Type: Article

References (49)

1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97 Suppl 11 (2002) S1-S5
2. Everhart J.E., and Renault P.F. Irritable bowel syndrome in officebased practice in the United States. Gastroenterology 100 (1991) 998-1005
3. Thompson W.G. The treatment of irritable bowel syndrome. Aliment Pharmacol Ther 16 (2002) 1395-1406
4. Longstreth G.F., and Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates. Dig Dis Sci 38 (1993) 1581-1589
5. Mitchell C.M., and Drossman D.A. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 92 (1987) 1282-1284
6. Thompson W.G., Irvine E.J., Pare P., et al. Functional gastrointestinal disorders in Canada: First populationbased survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 47 (2002) 225-235
7. Whitehead W.E., Burnett C.K., Cook III E.W., and Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 41 (1996) 2248-2253
8. Jones R.H. Clinical economics review: Gastrointestinal disease in primary care. Aliment Pharmacol Ther 10 (1996) 233-239
9. Dean B.B., Aguilar D., Barghout V., et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 11 Suppl 1 (2005) S17-S26
10. Frank L., Kleinman L., Rentz A., et al. Health-related quality of life associated with irritable bowel syndrome: Comparison with other chronic diseases. Clin Ther 24 (2002) 675-689
11. Gralnek I.M., Hays R.D., Kilbourne A., et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119 (2000) 654-660
12. Hahn B.A., Yan S., and Strassels S. Impact of irritable bowel syndrome on qualiry of life and resource use in the United States and United Kingdom. Digestion 60 (1999) 77-81
13. Hungin A.P., Whorwell P.J., Tack J., and Mearin F. The prevalence, patterns and impact of irritable bowel syn drome: An international survey of 40,000 subjects. Aliment Pharmacol Ther 17 (2003) 643-650
14. Inadomi J.M., Fennerty M.B., and Bjorkman D. Systematic review: The economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 18 (2003) 671-682
15. Khoshoo V., Armstead C., and Landry L. Effect of a laxative with and with out tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 23 (2006) 191-196
16. Frissora C.L. Diagnosis, treatment, and management of irritable bowel syndrome with constipation and chronic constipation. Med Gen Med 7 (2005) 71
17. Muller-Lissner S.A., Fumagalli I., Bardhan K.I.D., et al. Tegaserod, a 5HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 15 (2001) 1655-1666
18. Novick J., Miner P., Krause R., et al. A randomized, double-blind, placebocontrolled trial of tegaserod in fe male patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 16 (2002) 1877-1888
19. Kellow J., Lee O.Y., Chang F.Y., et al. An Asia-Pacific, double-blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 52 (2003) 671-676
20. Tack J., Muller-Lissner S., Bytzer P., et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 54 (2005) 1707-1713
21. e-CPS Compendium of Pharmaceuticals and Specialties, Drug Monographs [database online] (2006), Canadian Pharmacists Association, Ottawa, ON
22. Pare P., Lam S.Y., Balshaw R., et al. Development and validation of a questionnaire to evaluate severity of symptoms in patients with IBS-C and IBS-A. Value Health 8 (2005) A8
23. Patrick D.L., Drossman D.A., Frederick I.O., et al. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig Dis Sci 43 (1998) 400-411
24. Drossman D.A., Patrick D.L., Whitehead W.E., et al. Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire. Am J Gastroenterol 95 (2000) 999-1007
25. The EuroQoL Group. EuroQoL-a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208
26. Brooks R. EuroQol:The currentstate of play. Health Policy 37 (1996) 53-72
27. Dolan P. Modeling valuations for EuroQol health states. Med Care 35 (1997) 1095-1108
28. Konig H.H., Ulshofer A., Gregor M., et al. Validation of the EuroQol questionnaire in patients with inflamma tory bowel disease. Eur J Gastroenterol Hepatol 14 (2002) 1205-1215
29. Hurst N.P., Kind P., Ruta D., et al. Measuring health-related quality of life in rheumatoid arthritis: Validity, responsiveness and reliability of EuroQol (EQ-SD). Br J Rheumatol 36 (1997) 551-559
30. Wu A.W., Jacobson K.L., Frick K.D., et al. Validity and responsiveness of the EuroQol as a measure of health related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res 11 (2002) 273-282
31. Bushnell D.M., Martin M.L., Ricci J.F., and Bracco A. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health 9 (2006) 90-97
32. Reilly M.C., Bracco A., Ricci J.F., et al. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire-irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther 20 (2004) 459-467
33. Reilly M.C., Tanner A., and Meltzer F.O. Work, classroom and activity impairment instruments: Validation studies in allergic rhinitis. Clin Drug Invest 11 (1996) 278-288
34. Wahlqvist P., Carlsson J., Stalhammar N.O., and Wiklund I. Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)-results from a cross-sectional study. Value Health 5 (2002) 106-113
35. Reilly M.C., Lavin P.T., Kahler K.I.T., and Pariser D.M. Validation of the Dermatology Life Quality Index and the Work Productivity and Activity Impairment-Chronic Hand Dermatitis Questionnaire in chronic hand dermatitis. J Am Acad Dermatol 48 (2003) 128-130
36. Williams R.E., Black C.L., Kim H.Y., et al. Stability of irritable bowel syndrome using a Rome II-based classi fication. Aliment Pharmacol Ther 23 (2006) 197-205
37. Mearin F., Baro E., Roset M., et al. Clinical patterns over time in irritable bowel syndrome: Symptom instability and severity variability. Am J Gastroenterol 99 (2004) 113-121
38. Talley N.J. A unifying hypothesis for the functional gastrointestinal disorders: Really multiple diseases or one irritable gut?. Rev Gastroenterof Disord 67 (2006) 72-78
39. Vandvik P.O., Wilhelmsen I., Ihlebaek C., and Farup P.G. Comorbidity of irritable bowel syndrome in general practice: A striking feature with clinical implications. Aliment Pharmacof Ther 20 (2004) 1195-1203
40. Locke III G.R., Zinsmeister A.R., Fett S.L., et al. Overlap of gastrointestinal symptom complexes in a US com munity. Neurogastroenterof Motif 17 (2005) 29-34
41. Akehurst R.L., Brazier J.E., Mathers N., et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmaco Economics 20 (2002) 455-462
42. Reilly M.C., Barghout V., McBurney C.R., and Niecko T.E. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 22 (2005) 373-380
43. Kobelt G., Andlin-Sobocki P., and Maksymowych W.P. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 33 (2006) 289-295
44. Lamers L.M., Meerding W.J., Severens J.L., and Brouwer W.B. The relationship between productivity and health-related quality of life: An empirical exploration in persons with low back pain. Qual Life Res 14 (2005) 805-813
45. McDermott A.M., Toelle T.R., Rowbotham D.J., et al. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain 10 (2006) 127-135
46. Kartman B., Gatz G., and Johannesson M. Health state utilities in gastroesophageal reflux disease patients with heartburn: A study in Germany and Sweden. Med Decis Making 24 (2004) 40-52
47. Hazell M., Frank T., and Frank P. Health related quality of life in individuals with asthma related symptoms. Respir Med 97 (2003) 1211-1218
48. Copenhagen, Denmark. Bracco A., Reilly M.C., McBurney C., and Ambegaonkar B. Burden of irritable bowel syndrome with constipation on health care resource utilisation, work productivity and activity impairment and quality of life in France, Germany and United Kingdom. Presented at: United European Gastroenterology Week (October 15-19, 2005)
49. Montreal, Canada. Bracco A., Reilly M.C., McBurney C., and Ambegaonkar B. Burden of irritable bowel syndrome with constipation on health care resource utilization, work productivity and activity impairment and quality of life. Presented at: 13th World Congress of Gastroenterology (September 10-14, 2005)